Galapagos loses Roche and misses profit target
This article was originally published in Scrip
Executive Summary
Galapagos of Belgium saw its share price slump as it hit investors with a double whammy: not only had it lost one of its five big pharma strategic alliance partners, Roche, but it had also failed to deliver on its 2012 income target. The broad-focused drug discovery and development company saw its share price slump 8.8% to €18.60 by midday trading on Euronext on 8 March.